Nanoform Finland will convene an extraordinary general meeting (EGM) on November 17 to elect Jeanne Thoma as a new board member.
“Following the successful completion of our clinical trial and commercial expansion, we’ve reached an exciting point in Nanoform’s growth trajectory and are delighted to welcome Ms. Thoma as a new board member during this busy time. Her remarkable career speaks for itself, and her insights will be invaluable as we continue on our mission to touch the lives of a billion patients worldwide through our game-changing nanoforming technologies,” says Edward Hæggström, Nanoform CEO.
Jeanne Thoma is a renowned global executive in the pharma industry according to Nanoform, and she spent the first part of her career at BASF in New Jersey, USA, where she rose to leadership positions in the pharmaceutical ingredients business, including within global sales, marketing, manufacturing operations, and supply chain. Thoma holds dual US and Irish citizenship.
After almost 15 years at BASF, Thoma moved to Basel, Switzerland, to join Lonza AG, starting as Executive Vice President and CHRO in charge of human resources globally, before taking responsibility as COO and President of the Microbial Control Sector, a CHF 1.6bn business with 30 sites and 3000 employees in 23 countries. During her time at Lonza, Thoma was a member of the Lonza AG Management Committee, reporting directly to the CEO. After more than 10 years in Basel, she returned to the US to work as an advisor on finance and M&A matters, before again taking an operative role, this time as President and CEO of SPI Pharma, a global pharmaceutical ingredients company in Wilmington, DE, US.
Today Thoma serves as independent director on the boards of ANI Pharmaceuticals Inc., Avid Bioservices Inc. and Vectura Group Plc. Jeanne has served two four-year terms on the Board of Directors for DCAT (Drug, Chemical & Associated Technologies Association, Inc.) and she currently serves as a member of the Board of Advisors to DCAT.
“Patients stand to benefit greatly from increased uptake of technological innovations in pharma. In my role as board member, I look forward to being a part of Nanoform’s journey, developing life-changing therapeutics and transforming patients’ lives by continuing to expand the reach of its unique nanoforming technologies,” says Jeanne Thoma.